C WorldWide Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

C WorldWide Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-38,168	Closed	-$2.65M	–	104
2019 Q1	$2.65M	Buy	38,168 +16,403	+75%	+$937K	0.03%	81
2018 Q4	$946K	Sell	21,765 -22,585	-51%	-$1.23M	0.01%	101
2018 Q3	$3.39M	Sell	44,350 -8,484	-16%	-$690K	0.04%	79
2018 Q2	$4.06M	Sell	52,834 -9,143	-15%	-$591K	0.06%	74
2018 Q1	$3.16M	Sell	61,977 -9,463	-13%	-$477K	0.05%	66
2017 Q4	$3.31M	Sell	71,440 -6,251	-8%	-$307K	0.05%	69
2017 Q3	$4.14M	Buy	77,691 +764	+1%	+$45.3K	0.06%	71
2017 Q2	$4.78M	Buy	76,927 +18,257	+31%	+$1.1M	0.07%	62
2017 Q1	$3.98M	Buy	58,670 +4,445	+8%	+$339K	0.07%	63
2016 Q4	$3.81M	Sell	54,225 -21,275	-28%	-$1.51M	0.07%	61
2016 Q3	$5.36M	Buy	75,500 +14,500	+24%	+$926K	0.09%	50
2016 Q2	$2.98M	Buy	61,000 +21,000	+53%	+$1.36M	0.06%	62
2016 Q1	$2.53M	Hold	40,000	–	–	0.05%	62
2015 Q4	$4.49M	Hold	40,000	–	–	0.08%	56
2015 Q3	$3.85M	Buy	+40,000	New	+$4.58M	0.06%	62

Other funds holding RARE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

C WorldWide Group's RARE Position: Q2 2019 in Review

C WorldWide Group sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2019, closing a stake of 38,168 shares — an estimated $2.65M sold.

C WorldWide Group first reported a position in RARE in Q3 2015 and held it in 15 quarters. The position peaked at $5.36M in Q3 2016. 170 funds tracked by Wall St. Rank hold RARE as of Q2 2019.

C WorldWide Group reported no remaining Ultragenyx Pharmaceutical position as of Q2 2019 after selling out during the quarter.
C WorldWide Group sold 38,168 Ultragenyx Pharmaceutical shares in Q2 2019, an estimated $2.65M.
C WorldWide Group first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 15 quarters.
C WorldWide Group's Ultragenyx Pharmaceutical position peaked at $5.36M in Q3 2016.
170 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2019.

Based on C WorldWide Group's 13F filing for Q2 2019, filed 2 Aug 2019.